Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.14
+0.03 (0.59%)
May 26, 2026, 4:00 PM EDT - Market closed
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Lexeo Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $20.6. The average 1-year stock price forecast is 300.78% higher than the current stock price, while the lowest is $12 (+133.46%) and the highest is $30 (+483.66%).
Price Target: $20.6 (+300.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lexeo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $17 | Buy | Maintains | $17 | +230.74% | May 12, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $20 | Buy | Maintains | $20 | +289.11% | May 12, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $17 | Buy | Reiterates | $17 | +230.74% | May 11, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $20 | Buy | Reiterates | $20 | +289.11% | Mar 31, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $19 | Buy | Maintains | $19 | +269.65% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
10.05M
EPS This Year
-1.21
from -1.86
EPS Next Year
-1.29
from -1.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 57.8M | ||||||
| Avg | n/a | 10.1M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.04 | -0.83 | ||||||
| Avg | -1.21 | -1.29 | ||||||
| Low | -1.40 | -1.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.